Result of Annual General Meeting

About this update from Oxford Biomedica Plc

  OXB Result of Annual General Meeting and Confirmation of Board Changes   Oxford, UK - 11 June 2025:  OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that all proposed resolutions were duly passed at its Annual General Meeting ("AGM"), held at 3 pm on 11 June 2025 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote .   The full text of all the resolutions can be viewed in the Notice of AGM by visiting the Company's website at www.oxb.com   Copies of the document setting out the above resolutions passed at the 2025 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism   On the Record Date (9 June 2025) there were 106,127,365 ordinary shares of 50 pence each in issue, each carrying one vote per share.   Further to the announcement by the Company on 9 April 2025, Stuart Henderson has stepped down from the Company's Board of Directors (the "Board") with immediate effect following the conclusion of today's AGM.   Following Stuart Henderson's departure, Colin Bond, who joined the Board as an Independent Non-Executive Director in January 2025, will succeed Mr. Henderson as Audit Committee Chair and Peter Soelkner, who joined the Board as an Independent Non-Executive Director in March 2024, will assume the position of Vice Chair. These changes are effective immediately.             Resolutions Votes For (incl. votes at the Chair's discretion)       % of votes cast Votes Against       % of votes cast Votes Withheld* Total votes cast** Result   Ordinary resolutions             1 To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2024, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports.  78,099,206 99.99%         4,993 0.01%         247,911         78,104,199       PASS 2 To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) for the financial year ended 31 December 2024.  71,581,194 91.65%  6,517,342 8.35%           253,574           78,098,536   PASS 3 To appoint Colin Bond as a Director of the Company.  78,094,045 99.98%       15,037 0.02%             243,028  78,109,082 PASS 4 To appoint Dr. Lucinda Crabtree as a Director of the Company.  78,099,379 99.99%         9,573 0.01%             243,158  78,108,952 PASS 5 To appoint Laurene Espinasse as a Director of the Company.  78,091,686 99.98%       17,593 0.02%             242,831  78,109,279 PASS 6 To reappoint Dr. Roch Doliveux as a Director of the Company.  77,646,951 99.42%     453,708 0.58%             251,451  78,100,659 PASS 7 To reappoint Professor Dame Kay Davies as a Director of the Company.  77,659,388 99.42%     450,237 0.58%   242,485   78,109,625 PASS 8 To reappoint Dr. Frank Mathias as a Director of the Company.  77,592,469 99.34%     513,155 0.66%   246,486   78,105,624 PASS 9 To reappoint Robert Ghenchev as a Director of the Company.  78,087,996 99.98% 15,604 0.02%   248,510   78,103,600 PASS 10 To reappoint Namrata Patel as a Director of the Company.  78,088,438 99.98%       19,162 0.02%             244,510  78,107,600 PASS 11   To reappoint Dr. Heather Preston as a Director of the Company.  77,160,176 98.78%     949,193 1.22%             242,741  78,109,369 PASS 12 To reappoint Peter Soelkner as a Director of the Company.  77,682,985 99.46%     420,357 0.54%             248,768  78,103,342 PASS 13 To appoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the 2025 AGM until the conclusion of the next AGM of the Company at which the accounts are laid.  78,091,769 99.98%       12,197 0.02%         248,144         78,103,966 PASS 14 To authorise the Audit Committee for and on behalf of the Board to determine the auditor's remuneration.  78,093,125 99.99%         6,387 0.01%     252,598     78,099,512 PASS 15 To authorise the Directors to allot shares.  78,082,788 99.97%       20,326 0.03%             248,996  78,103,114 PASS   Special resolutions   16 To authorise the Directors to disapply pre-emption rights.  78,024,010 99.90%       76,292 0.10%             251,808  78,100,302 PASS 17 To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.  78,021,831 99.89%       82,729 0.11%     247,550     78,104,560 PASS 18 To amend the Articles by deleting the existing articles 43.2 and 43.4G and replacing them with new articles 43.2 and 43.4G respectively.  78,024,468 99.91%       72,785 0.09%     254,857     78,097,253 PASS 19 To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.  78,052,385 99.92%       59,729 0.08%     239,996     78,112,114 PASS * A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.   -Ends-   Enquiries:        OXB: Natalie Walter, Company Secretary - T : +44 (0) 1865 783 000 / E: [email protected] ICR Healthcare: T: +44 (0)20 3709 5700 / E:  [email protected] Mary-Jane Elliott / Angela Gray / Davide Salvi     About OXB   OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.   One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector de velopment and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early - stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.   OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetra V ecta™ system), a dual - plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.   OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com , and follow us on LinkedIn and YouTube.

View stock analysis, news, and events for Oxford Biomedica Plc